New observations concerning the interpretation of magnetic resonance spectroscopy of meningioma

This study was aimed to clarify some ambiguities in the interpretation of proton magnetic resonance spectroscopy (1H-MRS) of meningiomas. The cases of 31 meningioma patients (27 benign and 4 nonbenign meningiomas) that underwent single-voxel 1H-MRS (PRESS sequence, TR/TE = 2,000 ms/68, 136, 272 ms) were retrospectively analyzed. To verify the findings of in-vivo study, phantoms were measured, and pathological sections of 11 patients were reviewed. All meningiomas demonstrated increased choline and decreased creatine, except for a lipomatous meningioma that only displayed a prominent lipid (Lip) peak. Alanine (Ala) and lactate (Lac) coexisted in eight cases, indicating an alternative pathway of energy metabolism in meningiomas. They partially overlapped with each other and demonstrated a triplet-like spectral pattern, which was consistent with phantom study. Glutamine/glutamate (Glx) was helpful for the recognition of meningioma when Ala was absent. N-acetyl compounds(NACs) were observed in nine cases whose voxels were completely limited within the tumors, indicating that meningiomas might have endogenous NACs. Lac was indicative of an aggressive meningioma, although not always a nonbenign one. Lip not only represented micronecrosis in nonbenign meningiomas, but also reflected microcystic changes or fatty degeneration in benign meningiomas. 1H-MRS reflects some distinctive biochemical and pathological changes of meningiomas that might be misinterpreted.

[1]  O Henriksen,et al.  In vivo quantification of brain metabolites by 1H-MRS using water as an internal standard. , 1993, Magnetic resonance imaging.

[2]  J. Peeling,et al.  1H NMR properties of N‐acetylaspartylglutamate in extracts of nervous tissue of the rat , 1992, NMR in biomedicine.

[3]  Carles Arús,et al.  Proton magnetic resonance spectroscopy (1H MRS) of human brain tumours: assessment of differences between tumour types and its applicability in brain tumour categorization , 2003, European Radiology.

[4]  A R Tate,et al.  Magnetic resonance spectroscopy of brain hemangiopericytomas: high myoinositol concentrations and discrimination from meningiomas. , 2001, Journal of neurosurgery.

[5]  Mathias Hoehn,et al.  Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation , 2005, NMR in biomedicine.

[6]  B. Miller A review of chemical issues in 1H NMR spectroscopy: N‐acetyl‐l‐aspartate, creatine and choline , 1991, NMR in biomedicine.

[7]  S Cerdán,et al.  Nonhistological diagnosis of human cerebral tumors by 1H magnetic resonance spectroscopy and amino acid analysis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  A. Llombart‐Bosch,et al.  Histopathological and Cytogenetic Findings in Benign, Atypical and Anaplastic Human Meningiomas: A Study of 60 Tumors , 2000, Journal of Neuro-Oncology.

[9]  P. Black,et al.  Epidemiology of intracranial meningioma. , 2005, Neurosurgery.

[10]  R. Kauppinen,et al.  Quantitative Metabolite Patterns of Human Brain Tumors: Detection by 1H NMR Spectroscopy In Vivo and In Vitro , 1994, Journal of computer assisted tomography.

[11]  G Friedmann,et al.  Human brain tumors: spectral patterns detected with localized H-1 MR spectroscopy. , 1992, Radiology.

[12]  Hidehiko Kajiwara,et al.  Proton Magnetic Resonance Spectroscopy of Brain TumorsAn In Vitro Study , 1994 .

[13]  V. L. Doyle,et al.  Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy , 2003, Magnetic resonance in medicine.

[14]  J. Frahm,et al.  Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors. , 1989, Radiology.

[15]  B. Scheithauer,et al.  Lipomatous Meningioma: A Clinicopathologic Study of 18 Cases With Special Reference to the Issue of Metaplasia , 2001, The American journal of surgical pathology.

[16]  J. Roda,et al.  Malignant and atypical meningiomas: a reappraisal of clinical, histological, and computed tomographic features. , 1987, Neurosurgery.

[17]  F. Howe,et al.  Detection of elevated glutathione in meningiomas by quantitative in vivo 1H MRS , 2003, Magnetic resonance in medicine.

[18]  H. Poptani,et al.  Cystic intracranial mass lesions: possible role of in vivo MR spectroscopy in its differential diagnosis. , 1995, Magnetic resonance imaging.

[19]  H. Mehdorn,et al.  MR spectroscopy in patients with intracranial meningiomas , 2007, Neurological research.

[20]  J. Hesselink,et al.  Utilization of glutamate/creatine ratios for proton spectroscopic diagnosis of meningiomas , 2007, Neuroradiology.

[21]  R. Gonzalez,et al.  Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Y. Kinoshita,et al.  Absolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy , 1997, NMR in biomedicine.

[23]  J. Sorenson,et al.  Localized 2D J-resolved 1H MR spectroscopy: strong coupling effects in vitro and in vivo. , 1995, Magnetic resonance imaging.

[24]  C. Arús,et al.  Utility of proton MR spectroscopy in the diagnosis of radiologically atypical intracranial meningiomas , 2003, Neuroradiology.

[25]  Gi-Hwan Choi,et al.  (1)H-MRS metabolic patterns for distinguishing between meningiomas and other brain tumors. , 2003, Magnetic resonance imaging.

[26]  M. Preul,et al.  FLUORESCENT IN SITU HYBRIDIZATION AND EX VIVO 1H MAGNETIC RESONANCE SPECTROSCOPIC EXAMINATIONS OF MENINGIOMA TUMOR TISSUE: IS IT POSSIBLE TO IDENTIFY A CLINICALLY‐AGGRESSIVE SUBSET OF BENIGN MENINGIOMAS? , 2007, Neurosurgery.

[27]  J. Hesselink,et al.  Malignant meningiomas: CT and histologic criteria, including a new CT sign. , 1982, AJNR. American journal of neuroradiology.

[28]  M. Hoehn,et al.  1H‐ and 31P‐MR spectroscopy of primary and recurrent human brain tumors in vitro: malignancy‐characteristic profiles of water soluble and lipophilic spectral components , 2001, NMR in biomedicine.

[29]  R. Schober,et al.  Cystic changes and vascular permeability in meningiomas. , 1988, Clinical neuropathology.

[30]  A. Falini,et al.  Proton magnetic resonance spectroscopy and intracranial tumours: Clinical perspectives , 1996, Journal of Neurology.

[31]  Jimmy D Bell,et al.  Approaches to editing, assignment and interpretation of proton spectra , 1991, NMR in biomedicine.

[32]  Y. Itai,et al.  Chronological change of brain abscess in 1H magnetic resonance spectroscopy , 2002, Neuroradiology.

[33]  Stephen Ashwal,et al.  Proton Magnetic Resonance Spectroscopy: An Emerging Technology in Pediatric Neurology Research , 1998, Pediatric Research.

[34]  T R Brown,et al.  Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. , 1996, Journal of neurosurgery.

[35]  S. Morikawa,et al.  Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy. , 1999, Journal of neurosurgery.

[36]  A. Dinçer,et al.  Single voxel proton MR spectroscopy findings of typical and atypical intracranial meningiomas. , 2006, European journal of radiology.

[37]  J Hennig,et al.  Human brain tumors: assessment with in vivo proton MR spectroscopy. , 1993, Radiology.

[38]  P. Sundgren,et al.  Magnetic resonance spectroscopy. , 2005, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[39]  M. Castillo,et al.  Clinical applications of proton MR spectroscopy. , 1996, AJNR. American journal of neuroradiology.

[40]  M. Hartmann,et al.  [Magnetic resonance spectroscopy of brain tumours]. , 2005, Der Nervenarzt.

[41]  Y. Kinoshita,et al.  Proton magnetic resonance spectroscopy of brain tumors: an in vitro study. , 1994, Neurosurgery.